trending Market Intelligence /marketintelligence/en/news-insights/trending/ma36an5f4hv9scgy8mngag2 content esgSubNav
In This List

aTyr chief scientific officer resigns

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


aTyr chief scientific officer resigns

San Diego's aTyr Pharma Inc. said David King resigned as the chief scientific officer of the company, effective Dec. 31.

The drug developer said King resigned to pursue founding a private biotechnology company.

King will assist in transition activities and remain with aTyr as a scientific consultant into 2019.